NASDAQ · STOCK
Globus Medical
$78.81
52W $51.79 – $101.40
63/100
$10.63B
18.1
0.95
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is GMED Bullish or Bearish?
Bullish.
Innellis AI committee rates Globus Medical (GMED) Buy with a composite score of 63/100
, based on 7 analysts with 71% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +12.45 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -7.55 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull & Bear Case
Bull Case
- EPS growing 221.2% YoY — Growth
- 4 consecutive earnings beats -- consistent execution — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
63/100
Agreement
71%
Analysts
7
Conviction
Moderate
Sector Rank
Top 4%
of 93 Healthcare peers
Value Analyst
bullish
62
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
Growth Analyst
bullish
66
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 221.2% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 17 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 62.2 to 62.5.
- New bearish signals: 2 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 3 appeared.
- Bearish pressure eased: 3 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst, Technical Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
- Technical Analyst: stance neutral->bullish; score 52->61 (+10); +1 bullish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
51.1
Neutral
MACD Histogram
0.455
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Lh Ll
Support
$75.43
Resistance
$80.00
Bollinger %B
0.59
Inside Bands
Price vs Moving Averages
EMA 9
$78.83
Below
EMA 21
$78.65
Above
EMA 50
$80.06
Below
EMA 200
$80.87
Below
Fundamental Analysis
Valuation
92
Growth
69
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio
18.1×
P/B Ratio
2.25×
PEG Ratio
0.08
Dividend Yield
0.00%
52W High
$101.40
52W Low
$51.79
Quality & Growth
ROE
11.8%
ROA
10.1%
Gross Margin
67.9%
Operating Margin
17.6%
Revenue Growth YoY
—
Debt / Equity
0.02
AI Fundamental Assessment
P/E ratio of 18.1 (inexpensive relative to a 15-40x range); Price-to-book of 2.3x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.7%; Current ratio of 4.56 (healthy short-term liquidity); Debt-to-equity of 0.02; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (4.43); Most recent quarter beat estimates by 19.4%; 4 consecutive earnings beats; EPS growth decelerating (+8.5% -> -12.5% QoQ); Analyst estimates rising over recent quarters
Get the Full GMED Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →